CTOs on the Move

Rhythm Pharmaceuticals

www.rhythmtx.com

 
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.rhythmtx.com
  • 222 Berkeley Street 12th Floor
    Boston, MA USA 02116
  • Phone: 857.264.4280

Executives

Name Title Contact Details
Taylor Cucchiara
Associate Director, Cybersecurity Profile

Funding

Rhythm Pharmaceuticals raised $41M on 02/17/2017
Rhythm Pharmaceuticals raised $37.5M on 06/16/2022

Similar Companies

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.

Human Genome Sciences

Human Genome Sciences, Inc. is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alvotech

Alvotech is a fully integrated specialty biopharmaceutical company focused on development and manufacturing of high quality biosimilar medicines.

Valitor

Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Our technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. We currently have development pipelines in the fields of dermatology, ophthalmology, orthopedics, and stem cell therapy that highlight the capabilities of our novel drug products.